Findings

What do systematic reviews say?

4,918 questions · 5,537 findings · 1,803 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,309 · 23.6%GRADE not reported 440 · 7.9%Very low 1,560 · 28.2%Low 1,292 · 23.3%Moderate 751 · 13.6%High 185 · 3.3%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Nitrate/nitrate derivatives vs placebo

Adverse events (3 weeks' · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 8 participants
GRADE not reported

Dopamine agonist plus co‐intervention vs co‐intervention

Any other adverse events · women undergoing assisted reproduction

It is very uncertain whether dopamine agonist plus co‐intervention changes any other adverse events compared with co‐intervention (very low certainty).

1 finding from 1 review

Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
OR 3.03 [0.12, 75.28]
2 studies · 366 participants
Very low

Dopamine agonist vs other active intervention

Any other adverse events · women undergoing assisted reproduction

1 finding from 1 review

Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 170 participants
GRADE not reported

Dopamine agonist vs placebo or no intervention

Any other adverse events · women undergoing assisted reproduction

It is very uncertain whether dopamine agonist changes any other adverse events compared with placebo/no intervention (very low certainty).

1 finding from 1 review

Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
OR 4.54 [1.49, 13.84]
2 studies · 264 participants
Very low

Ultrasound‐guided injection vs non‐image‐guided injection

Number of adverse events · Patients with shoulder pain

Ultrasound‐guided injection showed no clear difference in number of adverse events compared with non‐image‐guided injection (low certainty).

1 finding from 1 review

Image‐guided glucocorticoid injection versus injection without image guidance for shoulder pain 2021 · Cochrane Headline outcomes only
RR 0.72 [0.4, 1.28]
5 studies · 402 participants
Low

Urtoxazumab (3.0 mg/kg) vs placebo

Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli

Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 71 participants
Low

Urtoxazumab (1.0 mg/kg) vs placebo

Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 74 participants
Low

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to lower adverse Events grade 3‐4 compared with chemotherapy (low certainty).

1 finding from 1 review

Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without… 2021 · Cochrane Headline outcomes only
RR 0.41 [0.33, 0.5]
5 studies · 3346 participants
Low

Active stimulation + other intervention vs other intervention alone

Adverse events:infection · adults with chronic pain

Active stimulation + other intervention may leads to higher adverse events:infection compared with other intervention alone (low certainty).

1 finding from 1 review

Implanted spinal neuromodulation interventions for chronic pain in adults 2021 · Cochrane Headline outcomes only
RR 4.83 [1.09, 21.4]
4 studies · 548 participants
Low

Colchicine plus standard care vs placebo or usual care

Serious adverse events ( · individuals with moderate or severe COVID‐19

1 finding from 1 review

Colchicine for the treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Very low

Selenium vs placebo

Alopecia · healthy men

Selenium leads to higher adverse events: alopecia compared with placebo (high certainty).

1 finding from 1 review

Drugs for preventing lung cancer in healthy people 2020 · Cochrane Headline outcomes only
RR 1.28 [1.07, 1.53]
1 study · 17448 participants
High

Behavioural activation vs interpersonal, cognitive analytic, integrative

adverse events(12 weeks) · depression in adults

1 finding from 1 review

Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Behavioural activation vs placebo

adverse events(16 weeks) · depression in adults

1 finding from 1 review

Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
Low

Behavioural activation vs medication

adverse events(16 weeks) · depression in adults

1 finding from 1 review

Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 143 participants
Moderate

Systemic antibiotic (oral penicillin 500 mg) plus analgesic vs Placebo plus analgesic

Number of adverse events · Adults over 18 years presenting with a single tooth with a clinical diagnosis of irreversible pulpitis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic use for irreversible pulpitis 2019 · Cochrane All outcomes
Number of adverse events: Outcome not reported.
Studies not reported
No studies found

IV vs oral cyclophosphamide

Adverse events: Vomiting · idiopathic steroid‐resistant nephrotic syndrome in children

It is very uncertain whether IV changes adverse events: vomiting compared with oral cyclophosphamide (very low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 2.38 [0.35, 16.17]
2 studies · 61 participants
Very low

IV vs oral cyclophosphamide

Alopecia · idiopathic steroid‐resistant nephrotic syndrome in children

IV showed no clear difference in adverse events: alopecia compared with oral cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 1.5 [0.27, 8.22]
1 study · 50 participants
Low

Non‐payment for Hospital‐Acquired Conditions Program vs capitation without P4P

Adverse clinical events* · Hospitals

1 finding from 1 review

Pay for performance for hospitals 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Exercise vs no exercise

Serious adverse events ( · adult patients with an implantable cardioverter defibrillator

Exercise showed no clear difference in serious adverse events ( compared with no exercise at the end of the intervention (low certainty).

1 finding from 1 review

Exercise‐based cardiac rehabilitation for adult patients with an implantable cardioverter defibrillator 2019 · Cochrane Headline outcomes only
RR 1.05 [0.77, 1.44]
2 studies · 356 participants
Low

Exercise vs no exercise at longest available follow‐up

Serious adverse events ( · adult patients with an implantable cardioverter defibrillator

It is very uncertain whether exercise changes serious adverse events ( compared with no exercise at longest available follow‐up (very low certainty).

1 finding from 1 review

Exercise‐based cardiac rehabilitation for adult patients with an implantable cardioverter defibrillator 2019 · Cochrane Headline outcomes only
RR 0.81 [0.61, 1.08]
3 studies · 188 participants
Very low